Potential spillover effects on diagnostic delay for cancer during the NHS-Galleri trial: a quasi-experimental difference-in-differences study

Sean Mann,Joshua Eagan,Beth Ann Griffin

DOI: https://doi.org/10.1101/2024.11.06.24316784

2024-11-07

Abstract:Objective: To examine whether regions participating in the NHS-Galleri trial of a multi-cancer early detection test experienced changes in cancer diagnostic delay rates that could indicate the presence of spillover due to constraints on care delivery. Design: Quasi-experimental difference-in-differences analysis. Setting: NHS England, April 2021-September 2023. Participants: All 21 cancer alliance regions in NHS England, 8 of which participated in the trial and 13 of which did not. Main outcomes: Rates of cancer diagnostic delays, defined as the percentage of patient referrals for investigation of possible cancer that resulted in diagnostic resolution within 28 days of initial referral. A difference-in-differences analysis was used to compare diagnostic delay rates in regions that participated in the NHS-Galleri trial to regions that did not participate, before and after the start of the trial. Three primary analyses were conducted: for all types of suspected cancer; for the most commonly referred cancers (breast, skin, lower gastrointestinal); and for less commonly referred cancers (all other types). Results: We observed no significant differences in rates of diagnostic delay for all cancers or for the most commonly referred cancers. For less commonly referred cancers, the percentage of patients experiencing diagnostic delays increased from 32.6% to 35.1% in regions participating in the NHS-Galleri trial from the 6 months before to the 6 months after trial start, compared with a small reduction from 32.7% to 31.7% in regions that did not participate (adjusted difference 3.4 percentage points, 95% confidence interval 1.2 to 5.7). These differences persisted from 6 to 12 months after trial start and receded the following year. Conclusions: Regional participation in the NHS-Galleri trial was associated with a statistically significant increase in diagnostic delay rates for less commonly referred cancers in the first year of the trial, but not for cancer overall or the most commonly referred cancers. Rollout of the trial intervention may have increased demand for downstream diagnostic services and, in a capacity constrained environment, led to region-wide increases in delayed diagnosis for less commonly referred cancers. If patients in the control group faced delayed diagnosis as a result, this would represent spillover due to constraints on care delivery during the first year and could affect measurement of the trial's primary outcome, incidence of later stage cancer at time of diagnosis. This study underscores the importance of addressing spillover in clinical trials of interventions that affect availability of healthcare services.

Oncology